ESPR
Esperion Therapeutics Inc
NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$2.00
+4.71% today
Updated 2026-04-30
Market cap
$491.64M
P/E ratio
—
P/S ratio
1.22x
EPS (TTM)
$-0.11
Dividend yield
—
52W range
$1 – $4
Volume
6.1M
Esperion Therapeutics Inc (ESPR) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-5.63%
Operating margin
50.60%
ROE
-260.80%
ROA
9.31%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 1999 | — | $-10.67M | — | — | — |
| 2000 | $2000.00 | $-27.58M | -39,200.00% | -1,378,600.00% | -1,378,800.00% |
| 2001 | — | $-24.93M | — | — | — |
| 2002 | — | $-28.73M | — | — | — |
| 2011 | — | $-10.82M | — | — | — |
| 2012 | — | $-11.74M | — | — | — |
| 2013 | $4.98B | $-26.09M | 100.00% | -0.46% | -0.52% |
| 2014 | $0.00 | $-36.38M | — | — | — |
| 2015 | $0.00 | $-49.78M | — | — | — |
| 2016 | $0.00 | $-74.98M | — | — | — |
| 2017 | $0.00 | $-166.99M | — | — | — |
| 2018 | $184.47M | $-201.81M | 100.00% | -110.90% | -109.40% |
| 2019 | $148.36M | $-97.17M | 100.00% | -62.75% | -65.49% |
| 2020 | $227.55M | $-143.55M | 98.95% | -53.35% | -63.09% |
| 2021 | $78.45M | $-269.11M | 81.88% | -289.02% | -343.04% |
| 2022 | $75.47M | $-233.66M | 64.27% | -237.83% | -309.58% |
| 2023 | $116.33M | $-209.25M | 62.81% | -133.72% | -179.87% |
| 2024 | $332.31M | $-51.74M | 79.36% | 16.37% | -15.57% |
| 2025 | $403.13M | $-22.68M | 67.95% | 14.95% | -5.63% |